Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Spearhead 1 -tutkimus koehenkilöillä, joilla on pitkälle edennyt nivelsarkooma tai myksoidi/pyöresoluinen liposarkooma

tiistai 3. marraskuuta 2026 päivittänyt: USWM CT, LLC

Vaiheen 2 yksihaarainen avoin kliininen tutkimus ADP-A2M4 SPEAR™ T-soluista potilailla, joilla on pitkälle edennyt nivelsarkooma tai myksoidi/pyöreäsoluinen liposarkooma

This is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1, 2 and 3 ) or MRCLS (Cohort 1) .

Tutkimuksen yleiskatsaus

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

52

Vaihe

  • Vaihe 2

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

      • Madrid, Espanja, 28040
        • Start Madrid-FJD, Fundación Jimѐnez Díaz
      • Seville, Espanja, 41013
        • Hospital Universitario Virgen del Rocio
    • Catalonia
      • Barcelona, Catalonia, Espanja, 119-129
        • Hospital Universitari Vall D'Hebron
    • Ontario
      • Toronto, Ontario, Kanada, M5G 2M9
        • Princess Margaret Cancer Centre
      • Lyon, Ranska
        • Centre Leon Berard
      • Pessac, Ranska, 33604
        • Hospital Haut Leveque, CHU Bordeaux
      • Villejuif, Ranska, 94805
        • Gustave Roussy Cancer Center
      • London, Yhdistynyt kuningaskunta, NW1 2PG
        • UCLH Cancer Clinical Trials Unit
      • Manchester, Yhdistynyt kuningaskunta, M20 4BX
        • The Christie NHS Foundation Trust
    • California
      • Duarte, California, Yhdysvallat, 91010
        • City of Hope
      • Palo Alto, California, Yhdysvallat, 94305
        • Stanford Cancer Center
    • Colorado
      • Aurora, Colorado, Yhdysvallat, 80045
        • University of Colorado
    • Florida
      • Jacksonville, Florida, Yhdysvallat, 33612
        • Mayo Clinic Jacksonville
      • Tampa, Florida, Yhdysvallat, 33612
        • Moffitt Cancer Center
    • Illinois
      • Chicago, Illinois, Yhdysvallat, 60611
        • Northwestern University Robert H. Lurie Comprehensive Cancer Center
    • Maryland
      • Bethesda, Maryland, Yhdysvallat, 20892
        • National Cancer Institute
    • Massachusetts
      • Boston, Massachusetts, Yhdysvallat, 02114
        • Massachusetts General Hospital
      • Boston, Massachusetts, Yhdysvallat, 02215
        • Dana Farber Cancer Institute
    • Michigan
      • Ann Arbor, Michigan, Yhdysvallat, 48109
        • University of Michigan
    • Missouri
      • St Louis, Missouri, Yhdysvallat, 63110
        • Washington University School of Medicine
    • New York
      • New York, New York, Yhdysvallat, 10065
        • Memorial Sloan-Kettering Cancer Center
    • Ohio
      • Columbus, Ohio, Yhdysvallat, 43210
        • Ohio State University
    • Tennessee
      • Nashville, Tennessee, Yhdysvallat, 37212
        • Vanderbilt
    • Texas
      • Houston, Texas, Yhdysvallat, 77030
        • MD Anderson Cancer Center
    • Washington
      • Seattle, Washington, Yhdysvallat, 98109
        • Fred Hutch
    • Wisconsin
      • Milwaukee, Wisconsin, Yhdysvallat, 53226
        • Medical College of WI Froedtert Hospital

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

10 vuotta - 75 vuotta (Lapsi, Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Key Inclusion Criteria

  • Age ≥16 (10 years at selected sites) and <=75 years
  • Diagnosis of advanced synovial sarcoma (Cohort 1, Cohort 2 and Cohort 3) or myxoid liposarcoma / myxoid round cell liposarcoma (Cohort 1 only) confirmed by cytogenetics.
  • Previously received either an anthracycline or ifosfamide containing regimen.
  • Measurable disease according to RECIST v1.1 prior to lymphodepletion
  • HLA-A*02:01, HLA-A*02:02, HLA-A*02:03 or HLA-A*02:06 positive
  • Tumor shows MAGE-A4 expression confirmed by central laboratory. North America Only (United States and Canada): Tumor (either an archival specimen or a fresh biopsy) shows MAGE-A4 expression of ≥2+ staining in ≥30% of the cells by immunohistochemistry.
  • ECOG Performance Status of 0 or1. For subjects aged ≥10 to ≥16 years old:

Lansky Score ≥60%.

• Left ventricular ejection fraction (LVEF) ≥50%.

Note: other protocol defined Inclusion criteria may apply

Key Exclusion Criteria:

  • HLA-A*02:05 in either allele
  • Received or plans to receive the following therapy/treatment prior to leukapheresis or lymphodepleting chemotherapy: Cytotoxic chemotherapy, Tyrosine kinase inhibitor (TKI) (e.g. pazopanib), Immune therapy (including monoclonal antibody therapy, checkpoint inhibitors,), Anti-cancer Vaccine, Gene therapy using an integrating vector (subjects who have received a gene therapy using a lentiviral vector may be eligible for the study), Corticosteroids or any other immunosuppressive therapy, Investigational treatment or interventional clinical trial, Allogeneic hematopoietic stem cell transplant, Radiotherapy to the target lesions, Major surgery
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine, cyclophosphamide or other agents used in the study.
  • History of autoimmune or immune mediated disease
  • Symptomatic CNS metastases including leptomeningeal disease.
  • Other prior malignancy that is not considered by the Investigator to be in complete remission
  • Clinically significant cardiovascular disease
  • Uncontrolled intercurrent illness
  • Active infection with human immunodeficiency virus, hepatitis B virus, hepatitis C virus, or human T cell leukemia virus
  • Pregnant or breastfeeding

Note: other protocol defined Exclusion criteria may apply.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Ei käytössä
  • Inventiomalli: Yksittäinen ryhmätehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Autologiset geneettisesti muunnetut afamitresgeeni-autoleucel (aiemmin ADP-A2M4) SPEAR™ T-solut

Single infusion of autologous genetically modified afamitresgene autoleucel (previously ADP-A2M4) Dose: 1.0 x109 to 10x109 transduced by a single intravenous infusion

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Overall Response Rate (ORR) (Cohort 1)
Aikaikkuna: From T-cell infusion until disease progression/recurrence as of data cut off (up to 2 years). Response was assessed at Week 4, Week 8, Week 12, Week 16, and Week 24, and every 2 months +/- 28 days until confirmed disease progression.

Percentage of participants with confirmed tumor response (complete [CR] or partial [PR] response) to treatment as assessed using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Independent Radiologist review (Cohort 1)

From T-cell infusion until disease progression/recurrence as of data cut off (up to 2 years). Response was assessed at Week 4, Week 8, Week 12, Week 16, and Week 24, and every 2 months +/- 28 days until confirmed disease progression.

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Adverse Events (AE) Including Serious Adverse Events (SAE), SAE, and Adverse Events of Special Interest (AESI) (Cohort 1)
Aikaikkuna: AEs, SAEs, and AESIs were collected at each visit from the start of lymphodepletion of the first subject until the last subject discontinued the interventional phase in cohort 1 as of the safety cut off (up to 3.2 years).

An AE was defined as any untoward medical occurrence in a subject or clinical study participant temporally associated with the use of the study intervention, whether or not considered related to the study intervention. Therefore, an AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. The number of participants with AEs (including SAE), SAE and AESI including cytokine release syndrome, neurotoxicity, ICANS, prolonged cytopenia are presented.

AEs, SAEs, and AESIs were collected at each visit from the start of lymphodepletion of the first subject until the last subject discontinued the interventional phase in cohort 1 as of the safety cut off (up to 3.2 years).
The Number of Participants With Replication Competent Lentivirus (RCL)
Aikaikkuna: From T-cell infusion to months 3, 6, and 12 post-infusion, then annually post-infusion (up to 2.8 years as of the data cut off).

The presence of RCL was assessed by qPCR targeting a segment of the vesicular stomatitis virus glycoprotein (VSV G) coding sequence.

From T-cell infusion to months 3, 6, and 12 post-infusion, then annually post-infusion (up to 2.8 years as of the data cut off).
Insertional Oncogenesis (IO)
Aikaikkuna: From 10 months post T-cell infusion up to 20 months post T-cell infusion (as of the data cut off)

Deoxyribonucleic acid (DNA) from participants peripheral blood mononuclear cell (PBMC) samples was subjected to lentiviral vector integration site analysis by next-generation sequencing, thus evaluating both the clonality status of the transduced cell population and the genomic localization of individual integration sites. The count of participants with integration sites representing more than 5% of all unique sites is presented.

From 10 months post T-cell infusion up to 20 months post T-cell infusion (as of the data cut off)
Best Overall Response (BOR) (Cohort 1)
Aikaikkuna: From T-cell infusion until disease progression/recurrence as of data cut off (up to 2.6 years). Response was assessed at Week 4, Week 8, Week 12, Week 16, and Week 24, and every 2 months +/- 28 days until confirmed disease progression.

BOR is the best response recorded from the start of T-cell infusion until disease progression/recurrence as assessed by Independent Radiologist review. Response categories are confirmed CR, confirmed PR, stable disease and confirmed progressive disease (PD). Best overall response is a stable disease, if CR or PR are unconfirmed.

From T-cell infusion until disease progression/recurrence as of data cut off (up to 2.6 years). Response was assessed at Week 4, Week 8, Week 12, Week 16, and Week 24, and every 2 months +/- 28 days until confirmed disease progression.
Time to Response (TTR) (Cohort 1)
Aikaikkuna: From T-cell infusion until first documented confirmed CR or confirmed PR. Response was assessed at Week 4, Week 8, Week 12, Week 16, and Week 24, and every 2 months +/- 28 days until confirmed disease progression.

TTR was defined as the interval (weeks) from the date of T-cell infusion to the earliest date of the first documented confirmed CR or confirmed PR as assessed by Independent Radiologist review. TTR (in weeks) = [date of initial confirmed CR or PR - date of T-cell infusion + 1]/7.

From T-cell infusion until first documented confirmed CR or confirmed PR. Response was assessed at Week 4, Week 8, Week 12, Week 16, and Week 24, and every 2 months +/- 28 days until confirmed disease progression.
Duration of Response (DoR) (Cohort 1)
Aikaikkuna: From initial confirmed response (CR or PR) until PD (or censored date) as of data cut off.

DoR (in months) is defined as ((date of PD (or censoring) - date of initial confirmed CR/PR + 1)/365.25)*12 as assessed by Independent Radiologist review.

Outcome Measure not yet reached as participants are ongoing in study

From initial confirmed response (CR or PR) until PD (or censored date) as of data cut off.
Progression Free Survival (PFS) (Cohort 1)
Aikaikkuna: From T-cell infusion until first documented PD or death due to any cause (or censored date), whichever occurs first, as of data cut off (up to 2.6 years). Response was assessed at Week 4, 8,12,16, 24, and every 2 months until confirmed PD

PFS is defined as the time from T-cell infusion to the date of the first documentation of PD or death due to any cause, whichever occurs first, as assessed by Independent Radiologist review. PFS (in weeks) was calculated as (date of PD/death [or censored date] - first T-cell infusion date + 1)/7.

From T-cell infusion until first documented PD or death due to any cause (or censored date), whichever occurs first, as of data cut off (up to 2.6 years). Response was assessed at Week 4, 8,12,16, 24, and every 2 months until confirmed PD
Overall Survival (OS) (Cohort 1)
Aikaikkuna: From T-cell infusion to death due to any reason (or censored date) as of data cut off (up to 2.6 years).

OS is defined as the time from the date of T-cell infusion to the date of death (due to any reason) or censored date. OS in months was calculated as ((death date - first T-cell infusion date + 1)/365.25)*12.

Outcome Measure not yet reached as participants are ongoing in study

From T-cell infusion to death due to any reason (or censored date) as of data cut off (up to 2.6 years).
Peak Persistence (Cohort 1)
Aikaikkuna: From T-cell infusion to 3.2 years (as of data cut off).

Peak persistence of afamitresgene autoleucel cells was reported as vector copy numbers per microgram of genomic DNA from peripheral blood mononuclear cell (PBMC).

From T-cell infusion to 3.2 years (as of data cut off).
Time Taken to Achieve Peak Expansion of Genetically Engineered T-cells in PBMCs
Aikaikkuna: 2.5 years

Time taken to achieve peak expansion of genetically engineered T-cells in PBMCs by flow cytometry

2.5 years
Quantitation of Genetically Engineered T-cells in PBMCs
Aikaikkuna: 2.5 years

Quantitation of genetically engineered T-cells in PBMCs by flow cytometry

2.5 years
Time Taken to Achieve Peak Expansion of Genetically Engineered T-cells in PBMCs
Aikaikkuna: 2.5 years

Time taken to achieve peak expansion of genetically engineered T-cells in PBMCs by qPCR

2.5 years
In Vitro Diagnostic (IVD) Assay for Screening
Aikaikkuna: 2.5 years

Development and validation of the MAGE-A4 antigen expression companion diagnostic assay

2.5 years

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Tutkijat

  • Päätutkija: Dejka Araujo, MD, MD Anderson Cancer Center; Houston TX 77030

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Tiistai 13. elokuuta 2019

Ensisijainen valmistuminen (Todellinen)

Sunnuntai 29. elokuuta 2021

Opintojen valmistuminen (Arvioitu)

Torstai 1. huhtikuuta 2038

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Tiistai 9. heinäkuuta 2019

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Torstai 1. elokuuta 2019

Ensimmäinen Lähetetty (Todellinen)

Maanantai 5. elokuuta 2019

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Torstai 5. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Tiistai 3. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Joo

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa